VEGFA and cancer: High-risk cancer therapies, such as anthracyclines, which generate high levels of ROS and induce direct endothelial damage [22], platinum-based agents associated with vascular stiffness [70], and VEGF inhibitors that impair microvascular function [71], must be carefully evaluated for their cardiovascular implications.